Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Hospital practice (1995) - 1 Apr 2012

Uhry Sabrina, Bessereau Jacques, Camoin-Jau Laurence, Paganelli Franck, Bonello Laurent

Abstract excerpt

In patients with acute coronary syndromes undergoing percutaneous coronary intervention, the combination of aspirin and clopidogrel, a P2Y12 adenosine diphosphate (ADP) receptor antagonist, is the gold standard of antiplatelet therapy. Two more potent P2Y12 ADP receptor antagonists are now available. Pharmacodynamic studies have revealed a large interindividual variability in the biological response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Coronary Syndrome
Share to Evidence-Based Medicine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Percutaneous Coronary Intervention

Share to Platelet Function Tests

Share to Prasugrel Hydrochloride

Share to Purinergic P2Y Receptor Antagonists

Share to Receptors, Purinergic P2Y12

Share to Thiophenes

Source

Identifiers

PMID: 22615085
DOI: 10.3810/hp.2012.04.976

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.PMID 22615085Read ↗

Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?Semantic proximity Read ↗

Recent developments in the use of antiplatelet agents to prevent cardiovascular events.Semantic proximity Read ↗

High platelet reactivity and clinical outcome - fact and fiction.Semantic proximity Read ↗

Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey.Semantic proximity Read ↗

Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance.Semantic proximity Read ↗

Pharmacogenetics of Antiplatelet Therapy.Semantic proximity Read ↗

Optimisation of anti-platelet therapy in acute coronary syndromesSemantic proximity Read ↗

Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.Semantic proximity Read ↗

High on-clopidogrel platelet reactivity: genotyping can help to optimize antiplatelet treatment.Semantic proximity Read ↗

Personalized antiplatelet therapy: a scoping review on the role of platelet function testing and genotyping in acute coronary syndrome.Semantic proximity Read ↗

Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.Semantic proximity Read ↗

Response variability to P2Y12 receptor inhibitors: expectations and reality.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.